ARTICLE | Clinical News
Eidos starts Phase III of AG10 in TTR amyloid cardiomyopathy
March 1, 2019 8:01 PM UTC
Eidos Therapeutics Inc. (NASDAQ:EIDX) began the two-part Phase III ATTRibute-CM trial evaluating AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy.
The primary endpoint for the first part of the trial is the change from baseline in 6-minute walk distance (6MWD) at 12 months. For the second part, the primary endpoint is evaluating all-cause mortality and the frequency of cardiovascular-related hospitalizations at 30 months...
BCIQ Company Profiles
BCIQ Target Profiles